Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383245 | 1.00 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL17327306 | 1.00 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258306 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258302 | 0.90 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16969287 | 0.90 | DRD3 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL16762854 | 0.89 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL5531169 | 0.89 | DRD2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL4334143 | 0.89 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL2258441 | 0.88 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL899642 | 0.88 | DRD2 (0.49) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013068439-A1 | 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5, 4 -F] [1, 4] OXAZEPINE COMPOUNDS AS DGAT1 INHIBITORS | INTERVET INTERNATIONAL B.V. (NL) | 2013-05-16 | — | — | WO | disclosed |
| WO-2012138648-A1 | COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS | IRM LLC (BM) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012112364-A1 | LACTAM DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012112364-A1 | LACTAM DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012044567-A2 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| EP-2408744-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2185567-B1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010107768-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718645-B2 | Substituted bicyclolactam compounds | PFIZER INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197926-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATMENT OF DIABETES | DGAT1, ACAT1, DGAT2 | DRD2 2360/4885DRD3 1723/4885DRD1 1388/4885 |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DRD2 427/4885DRD3 666/4885DRD1 605/4885 |
| US-20090036425-A1 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DRD2 427/4885DRD3 666/4885DRD1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.